NLSP
NLSP
NLS Pharmaceutics AG • NASDAQ
$3.83 ▲ 9.43% (+0.33)
Market Cap $240803
52w High $43.40
52w Low $0.76
Dividend Yield 0%
P/E -0.22
Volume 30.34M
Outstanding Shares 316.01K
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $1.777M ▲ | $-2.221M ▼ | 0% | $-10.5 ▲ | $-2.218M ▼ |
| Q4-2024 | $0 | $1.583M ▼ | $55.024K ▲ | 0% | $-26.3 ▼ | $-1.585M ▲ |
| Q2-2024 | $0 | $2.048M ▼ | $-2.036M ▼ | 0% | $0 ▲ | $-1.943M ▲ |
| Q4-2023 | $0 | $4.258M ▼ | $-4.559K ▲ | 0% | $-1.4 ▲ | $-4.409M ▲ |
| Q2-2023 | $0 | $7.544M | $-7.613M | 0% | $-2 | $-7.544M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $3.072M ▲ | $4.338M ▲ | $1.455M ▲ | $2.883M ▲ |
| Q4-2024 | $1.665M ▲ | $2.233M ▲ | $826.764K ▼ | $1.406M ▲ |
| Q2-2024 | $552.758K ▼ | $1.193M ▼ | $10.462M ▼ | $-9.268M ▼ |
| Q4-2023 | $897.68K ▼ | $1.847M ▼ | $10.68M ▲ | $-8.834M ▼ |
| Q2-2023 | $1.651M | $2.27M | $6.557M | $-4.287M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-2.221M ▼ | $-2.074M ▲ | $0 ▲ | $3.481M ▼ | $1.407M ▲ | $-2.074M ▲ |
| Q4-2024 | $55.024K ▲ | $-2.737M ▼ | $-3.917K ▼ | $3.854M ▲ | $1.113M ▲ | $-2.741M ▼ |
| Q2-2024 | $-2.036M ▼ | $-1.53M ▲ | $0 | $1.186M ▼ | $-344.922K ▲ | $-1.53M ▼ |
| Q4-2023 | $-4.559K ▲ | $-2.388M ▲ | $0 | $1.634M ▲ | $-753.772K ▲ | $-2.387K ▲ |
| Q2-2023 | $-7.613M | $-7.297M | $0 | $0 | $-7.297M | $-7.297M |
Market Cap $240803
52w High $43.40
52w Low $0.76
Dividend Yield 0%
P/E -0.22
Volume 30.34M
Outstanding Shares 316.01K
About NLS Pharmaceutics AG
https://nlspharma.comNLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $1.777M ▲ | $-2.221M ▼ | 0% | $-10.5 ▲ | $-2.218M ▼ |
| Q4-2024 | $0 | $1.583M ▼ | $55.024K ▲ | 0% | $-26.3 ▼ | $-1.585M ▲ |
| Q2-2024 | $0 | $2.048M ▼ | $-2.036M ▼ | 0% | $0 ▲ | $-1.943M ▲ |
| Q4-2023 | $0 | $4.258M ▼ | $-4.559K ▲ | 0% | $-1.4 ▲ | $-4.409M ▲ |
| Q2-2023 | $0 | $7.544M | $-7.613M | 0% | $-2 | $-7.544M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $3.072M ▲ | $4.338M ▲ | $1.455M ▲ | $2.883M ▲ |
| Q4-2024 | $1.665M ▲ | $2.233M ▲ | $826.764K ▼ | $1.406M ▲ |
| Q2-2024 | $552.758K ▼ | $1.193M ▼ | $10.462M ▼ | $-9.268M ▼ |
| Q4-2023 | $897.68K ▼ | $1.847M ▼ | $10.68M ▲ | $-8.834M ▼ |
| Q2-2023 | $1.651M | $2.27M | $6.557M | $-4.287M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-2.221M ▼ | $-2.074M ▲ | $0 ▲ | $3.481M ▼ | $1.407M ▲ | $-2.074M ▲ |
| Q4-2024 | $55.024K ▲ | $-2.737M ▼ | $-3.917K ▼ | $3.854M ▲ | $1.113M ▲ | $-2.741M ▼ |
| Q2-2024 | $-2.036M ▼ | $-1.53M ▲ | $0 | $1.186M ▼ | $-344.922K ▲ | $-1.53M ▼ |
| Q4-2023 | $-4.559K ▲ | $-2.388M ▲ | $0 | $1.634M ▲ | $-753.772K ▲ | $-2.387K ▲ |
| Q2-2023 | $-7.613M | $-7.297M | $0 | $0 | $-7.297M | $-7.297M |
CEO
Alexander Zwyer
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
CEO
Alexander Zwyer
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public January 29, 2021
Method of going public IPO
Full time employees 6
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-10-31 | Reverse | 1:10 |
| 2024-09-27 | Reverse | 1:40 |
Institutional Ownership
Summary
% Of Shares Owned 0.01%
Total Number Of Holders 1
Only Showing The Top 1